These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9285228)

  • 21. Discounting in cost-utility analysis of healthcare interventions: reassessing current practice.
    Cohen BJ
    Pharmacoeconomics; 2003; 21(2):75-87. PubMed ID: 12515570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the Appropriate Measure to Estimate Hyperbolic Discounting Rate (
    Berk HR; Gupta TA; Sanabria F
    Perspect Behav Sci; 2021 Dec; 44(4):667-682. PubMed ID: 35098030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discounting of lives saved in future generations--some empirical results.
    Johannesson M; Johansson PO
    Health Econ; 1996; 5(4):329-32. PubMed ID: 8880169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valuing health care using willingness to pay: a comparison of the payment card and dichotomous choice methods.
    Ryan M; Scott DA; Donaldson C
    J Health Econ; 2004 Mar; 23(2):237-58. PubMed ID: 15019754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost utility analysis: what should be measured?
    Richardson J
    Soc Sci Med; 1994 Jul; 39(1):7-21. PubMed ID: 8066489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eliciting several willingness to pay in a single contingent valuation survey: application to health care.
    Luchini S; Protière C; Moatti JP
    Health Econ; 2003 Jan; 12(1):51-64. PubMed ID: 12483760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intertemporal discounting as a risk factor for high BMI: evidence from Australia, 2008.
    Dodd MC
    Econ Hum Biol; 2014 Jan; 12():83-97. PubMed ID: 23787352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention, policy, and paradox: what is the value of future health?
    Ganiats TG
    Am J Prev Med; 1997; 13(1):12-7. PubMed ID: 9037337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using multilevel models for assessing the variability of multinational resource use and cost data.
    Grieve R; Nixon R; Thompson SG; Normand C
    Health Econ; 2005 Feb; 14(2):185-96. PubMed ID: 15386660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis from a societal perspective.
    Johannesson M; O'Conor RM
    Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved modeling of in vivo confocal Raman data using multivariate curve resolution (MCR) augmentation of ordinary least squares models.
    Hancewicz TM; Xiao C; Zhang S; Misra M
    Appl Spectrosc; 2013 Dec; 67(12):1463-72. PubMed ID: 24359661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses.
    Bala MV; Zarkin GA; Mauskopf JA
    Value Health; 2002; 5(4):338-46. PubMed ID: 12102696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.
    Brouwer WB; Koopmanschap MA; Rutten FF
    Health Econ; 1997; 6(5):511-4. PubMed ID: 9353652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discounting in cost-effectiveness analysis of healthcare programmes.
    Katz DA; Welch HG
    Pharmacoeconomics; 1993 Apr; 3(4):276-85. PubMed ID: 10146991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valuation of health changes with the contingent valuation method: a test of scope and question order effects.
    Kartman B; Stålhammar NO; Johannesson M
    Health Econ; 1996; 5(6):531-41. PubMed ID: 9003940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of a statistical life: theoretical and empirical evidence.
    Johansson PO
    Appl Health Econ Health Policy; 2002; 1(1):33-41. PubMed ID: 14618746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valuing prevention: discounting health benefits and costs in New Zealand.
    Milne R
    N Z Med J; 2005 May; 118(1214):U1443. PubMed ID: 15886738
    [No Abstract]   [Full Text] [Related]  

  • 38. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics.
    Bridges JF
    Appl Health Econ Health Policy; 2003; 2(4):213-24. PubMed ID: 15119540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 40. The time trade-off: a note on the effect of lifetime reallocation of consumption and discounting.
    Dolan P; Jones-Lee M
    J Health Econ; 1997 Dec; 16(6):731-9. PubMed ID: 10176781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.